Roche starts 1,600-person phase 3 trontinemab trials

Iris monthly roundup · October 2026 · 140 scanned · 137 usable (36 research · 5 official · 88 news · 8 announcement)

In this report

October moved brain-delivery pharmacology into a pivotal test and pushed blood biomarkers further toward staging and routine diagnostic use. Large human single-cell datasets also sharpened the map from genetic risk to disease-relevant cell populations. Public funders paired platform research with NHS implementation trials, although the clinical value of these approaches remains to be demonstrated.

Roche began the 1,600-participant TRONTIER 1 and 2 phase 3 trials of TfR1-mediated brain delivery for trontinemab.
neurologylive.com
Plasma eMTBR-tau243 and p-tau205 were identified as later-stage tau markers, with eMTBR-tau243 most closely associated with tau PET and cognition.
nature.com
The PLASMAR randomised trial found that early disclosure of p-tau217 and NfL results improved diagnostic confidence and reduced follow-up testing in 220 participants.
barcelonabeta.org

Clinical trials and treatment development

Roche starts phase 3 trials of trontinemab

Clinical trials & regulatory decisions

Roche has initiated two phase 3 trials testing whether trontinemab's TfR1-mediated brain delivery can turn rapid plaque clearance into slower clinical progression. The programme is now large enough to provide a pivotal efficacy and safety readout, but its proposed reduction in ARIA risk remains a hypothesis for these trials to test.

TRONTIER 1 and 2 are planned to enrol 1,600 people with early symptomatic Alzheimer's disease and confirmed amyloid pathology.
The phase 1b/2a study reported rapid plaque clearance; the phase 3 programme uses induction-maintenance dosing derived from that result.

Sources: Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER…News

The trials extend anti-amyloid treatment development from antibody activity toward a direct test of brain delivery as a therapeutic variable.

Study identifies plasma markers for later tau stages

Biomarkers & diagnosis

A Nature Communications study identified plasma eMTBR-tau243 and p-tau205 as later-stage biomarkers aligned with fibrillar tau aggregation. eMTBR-tau243 showed the strongest associations with regional tau PET and cognition, supporting a staging role but not yet replacing PET-based assessment.

The markers rose later in the disease process than earlier plasma tau markers and were associated with longitudinal cognitive trajectories.
The authors propose combining p-tau217 with eMTBR-tau243 in a plasma tau staging system that tracks PET-based staging.

Sources: Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological stagi…Research

The study extends blood biomarker work from detecting Alzheimer biology toward estimating its stage and likely cognitive course.

PLASMAR tests early blood biomarker disclosure

Biomarkers & diagnosis

In the 220-participant PLASMAR trial, telling clinicians early about p-tau217 and NfL results improved diagnostic confidence and reduced follow-up testing without increasing reported distress. The effect was clearest among people with a low probability of Alzheimer's disease, where biomarker information helped close the diagnostic pathway sooner.

By three months, clinicians reached 90% diagnostic confidence in 50% of early-disclosure cases, compared with 4.6% in the delayed-disclosure group.
Early disclosure reduced unnecessary reassessments and additional tests, although implementation across different clinical services still needs evaluation.

Sources: Study shows that earlier disclosure of Alzheimer's blood biomarker res…News

The trial tests the operational value of blood biomarkers by changing when results enter routine clinical decision-making.

Mechanisms and genetics

PsychAD maps gene activity across eight brain diseases

Disease mechanisms & genetics

The NIH-funded PsychAD Consortium mapped gene activity in more than 6 million prefrontal-cortex cells from nearly 1,500 people across the lifespan and eight brain diseases. The atlas separates shared cellular responses from disease-specific changes, creating a human reference for testing mechanisms rather than inferring them from isolated models.

Severe Alzheimer's disease was associated with fewer neurons and more immune and vascular cells, while many shared disease changes involved basic cellular functions.
Gene activity changed rapidly from birth to age 24, was relatively stable in midlife, and shifted again after age 65.

Sources: Gene activity in brain diseases mapped | National Institutes of Health…Official

The resource links molecular changes to specific human brain cell populations across disease severity and age.

Garvan links genetic risk to immune cell types

Disease mechanisms & genetics

The Garvan Institute's TenK10K project analysed gene activity in more than 5 million immune cells from nearly 2,000 Australians and linked risk regions for 16 diseases to specific cell types. The work offers a route from statistical genetic association to candidate regulatory mechanisms, although disease-specific causal effects still require functional validation.

The studies identified nearly 1,500 genes and incorporated tandem repeats and chromatin accessibility alongside gene-expression data.
One example linked a variant that increases OSM expression in natural killer cells with higher irritable bowel disease risk, illustrating the method's resolution outside Alzheimer's disease.

Sources: Landmark studies map how genetic differences drive ...News

TenK10K extends genetic-risk mapping from genomic regions toward the immune cell types and regulatory features that may mediate risk.

Funding and implementation

UK funds NHS projects to accelerate dementia diagnosis

Research funding

The UK government launched an £80 million challenge supporting nine projects to test faster and more accurate dementia diagnosis in NHS settings. The programme sets an operational target, from 60% to 92% diagnosis within 18 weeks of referral, but funding beyond the initial stage depends on demonstrated effectiveness.

The projects include faster MRI scans and remote cognitive assessments, with real-world testing rather than laboratory-only validation.
Further funding will be conditional on performance, so the announcement establishes an evaluation programme rather than evidence that any selected tool works.

Sources: £80m challenge for faster, better dementia diagnosis launched – UKRIAnnouncement

The programme connects diagnostic innovation to implementation metrics, workforce constraints and a specified referral-to-diagnosis interval.

ARPA-H backs three Alzheimer's research projects

Research funding

ARPA-H announced up to $48.8 million for three projects spanning biomarker-guided trials, AI-enabled multi-omic analysis and a decentralised clinical trial. The awards expand its Alzheimer's portfolio to $155.3 million, but they are programme commitments rather than clinical evidence.

Mass General Brigham will develop a biomarker-guided clinical trial platform, Washington University an AI-enabled multi-omic data platform, and Bevimi a decentralised trial.
The projects aim to model disease trajectories, test preventative therapies and identify disease drivers; their value will depend on execution and validation.

Sources: ARPA-H invests in new Alzheimer’s projects to accelerate early detecti…Official

The package brings biomarker, computational and trial-delivery approaches into one public research portfolio.

How Iris covered your topics this month

Every topic you track was searched over the last month.

Topic

Sources found

In this briefing

Clinical trials & regulatory decisions

1 story

Biomarkers & diagnosis

2 stories

Disease mechanisms & genetics

2 stories

Risk factors & prevention

Nothing of notable significance

Dementia care research

Nothing of notable significance

Research funding

2 stories

Appendix: 86 sources relevant to you, from 140 scanned

Clinical trials & regulatory decisions · 28

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials · neurologylive.com · 2026-10-30News

Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80% - BioSpace · biospace.com · 2026-10-30 · 2 outletsNews

Eisai to Present New Five-Year Lecanemab Data and ... · prnewswire.com · 2026-10-29 · 2 outletsAnnouncement

A small-molecule TREM2 agonist for Alzheimer’s disease | Nature Medicine · nature.com · 2026-10-29 · 2 outletsNews

UK clinical trial reforms deliver seven-day approval for eligible trial modifications | News | European Pharmaceutical Review · europeanpharmaceuticalreview.com · 2026-10-29News

Six months since implementation of the UK’s new clinical trials regulations – MedRegs · medregs.blog.gov.uk · 2026-10-28Official

A phase III trial of ALZT-OP1 (cromolyn + ibuprofen) in early Alzheimer's disea… — JournalFilter · journalfilter.com · 2026-10-23News

Anti-amyloid drugs in 2026: where each one stands · alzhub.org · 2026-10-21News

World Dementia Council Update - Alzheimer's Association · alz-journals.onlinelibrary.wiley.com · 2026-10-21Research

MHRA to develop AI protocol checker for clinical trial sponsors · bioxconomy.com · 2026-10-21News

Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials - Taipei Medical University · hub.tmu.edu.tw · 2026-10-20Research

A phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB) | Alzheimer's Research & Therapy | Springer Nature Link · link.springer.com · 2026-10-20Research

More than just accuracy: A pathway-level framework for implementing blood and digital biomarkers for Alzheimer’s disease care · sciencedirect.com · 2026-10-20Research

Safety, short-term clinical outcomes, and associated factors of lecanemab: a multicenter real-world study from the Korean Joint Registry for Alzheimer’s Treatment and Diagnostics (JOY-ALZ) | Alzheimer's Research & Therapy | Springer Nature Link · link.springer.com · 2026-10-19Research

New Alzheimer's Drugs Slow Decline a Little: What Trials and Regulators Found · understandingaging.org · 2026-10-16News

Blood-based Alzheimer’s Disease Biomarkers: Updates and Opportunities - NIA IMPACT Collaboratory · impactcollaboratory.org · 2026-10-16News

Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop - BioSpace · biospace.com · 2026-10-15News

New Alzheimer's Drugs 2026: Treatment in Germany, Access & Cost · bookinghealth.com · 2026-10-15News

Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease | Science Translational Medicine · science.org · 2026-10-14 · 2 outletsResearch

Alzheimer's Disease - Focused Ultrasound Foundation · fusfoundation.org · 2026-10-14News

How should the results of Alzheimer's disease treatment trials ... · alz-journals.onlinelibrary.wiley.com · 2026-10-13Research

EU clinical trial advice pilot becomes permanent · clinicaltrialsarena.com · 2026-10-09News

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease | Neurology Clinical Practice · neurology.org · 2026-10-08Research

Longitudinal clinical outcomes after amyloid clearance in ... · alz-journals.onlinelibrary.wiley.com · 2026-10-07Research

Trials Update October 2026 | Being Patient · beingpatient.com · 2026-10-07News

FDA unveils program to address bottlenecks in clinical trials · bioprocessintl.com · 2026-10-05Announcement

FDA Delays Novo Nordisk's Denecimig Over Facility Fixes | BioPharm International · biopharminternational.com · 2026-10-05News

DHHS Releases 2026 Unified Agenda With Five Clinical Research Rule Changes · clinicaltrialvanguard.com · 2026-10-03News

Biomarkers & diagnosis · 20

Leveraging immunoprecipitation mass spectrometry and neuropathology to identify the clinical value of different blood tau species in Alzheimer’s disease | Journal of Neurology | Springer Nature Link · link.springer.com · 2026-10-31Research

Two-Step Blood Test Improves Specificity for Alzheimer's ... · labmedica.com · 2026-10-28News

Alzheimer’s biomarkers may help identify ALS, predict outcomes · alsnewstoday.com · 2026-10-27News

APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI | Neurological Sciences | Springer Nature Link · link.springer.com · 2026-10-23Research

Alzheimer's Blood Test Guidance: Who to Test and How · dementiaresearcher.nihr.ac.uk · 2026-10-23News

Study shows that earlier disclosure of Alzheimer's blood biomarker results speeds up diagnosis without increasing patient distress | BBRC · barcelonabeta.org · 2026-10-22News

Clinical performance and decision thresholds of an automated plasma p-tau217 assay for amyloid pathology in a Taiwanese memory clinic | Journal of Neurology | Springer Nature Link · link.springer.com · 2026-10-21Research

Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological staging and prognosis in Alzheimer’s disease | Nature Communications · nature.com · 2026-10-19Research

Etiologic Diagnosis of Dementia Practice Guideline · aan.com · 2026-10-19News

From prediction to mechanism: Explainable AI uncovers plasma and CSF proteomic signatures of Alzheimer's disease - ScienceDirect · sciencedirect.com · 2026-10-15Research

Alzheimer's Society - About the Blood Biomarker Challenge · bloodbiomarkerchallenge.org · 2026-10-15News

Global Study Validates Alzheimer’s Blood Test Across Racial Groups · clpmag.com · 2026-10-14News

Blood-based biomarkers for Alzheimer’s disease: use in primary care | Medicine Today · medicinetoday.com.au · 2026-10-12News

Frontiers | Noninvasive diagnosis of Alzheimer’s disease: a review of emerging biomarkers and multimodal approaches · frontiersin.org · 2026-10-08Research

SPLASH: a benchtop platform for accessible, ultrasensitive quantification of plasma biomarkers in Alzheimer’s disease | Scientific Reports · nature.com · 2026-10-07Research

A Plasma Biomarker Panel in Memory Clinics: Mixed Results | NEJM Clinician · clinician.nejm.org · 2026-10-07Research

Imaging remains crucial: Alzheimer's breakthrough doesn't end with a blood test - National Imaging Facility · anif.org.au · 2026-10-07News

Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders | Psychiatric Times · psychiatrictimes.com · 2026-10-07News

Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management · media.jamanetwork.com · 2026-10-05Research

Reducing Alzheimer’s diagnostic uncertainty with a sequential plasma p-tau217 workflow in real-world memory clinic practice | Alzheimer's Research & Therapy | Springer Nature Link · link.springer.com · 2026-10-02Research

Disease mechanisms & genetics · 13

Alzheimer’s disease genetics converges on microglial and neuronal dysregulation | Nature · nature.com · 2026-10-28 · 2 outletsResearch

Largest genetic study on Alzheimer’s identifies 48 new risk loci - VU Amsterdam · vu.nl · 2026-10-28 · 2 outletsNews

Alzheimer's disease genetics converges on microglial and neuronal dysregulation. · pubmed.ncbi.nlm.nih.gov · 2026-10-28 · 2 outletsResearch

Clinical genetics news · medicalxpress.com · 2026-10-28News

Gene activity in brain diseases mapped | National Institutes of Health (NIH) · nih.gov · 2026-10-27 · 5 outletsOfficial

Scientists are starting to unravel the most important genetic risk factor for Alzheimer's | Live Science · livescience.com · 2026-10-19News

How the biggest Alzheimer’s risk gene disrupts the process of insulating neurons – TSAI LABORATORY AT MIT · tsailaboratory.mit.edu · 2026-10-16News

Rare study reveals a striking divide inside an Alzheimer’s patient’s brain | ScienceDaily · sciencedaily.com · 2026-10-15News

Genetic risk and cognitive decline in Alzheimer's | Ace · acebarcelona.org · 2026-10-14News

Genome-wide analysis of common structural variants in Alzheimer’s disease identifies a risk-associated regulatory CCG repeat in FAM193B | Nature Neuroscience · nature.com · 2026-10-12Research

How tau's protein partners change in Alzheimer's | UK DRI · ukdri.ac.uk · 2026-10-12News

Herskowitz investigates neurofibrillary tangles contributing to Alzheimer’s disease | Heersink School of Medicine News · uab.edu · 2026-10-06Announcement

Genes May Protect Against ApoE4 Alzheimer’s Risk | Being Patient · beingpatient.com · 2026-10-05News

Research funding · 6

Alzheimer's Association Grants: LOI and 10% Cap — CASRAI · casrai.org · 2026-10-29News

Alzheimer's Research Program(AZRP) · ebrap.org · 2026-10-29News

Duke AITC Announces First National Request for Applications | Duke & UNC ADRC · dukeuncadrc.org · 2026-10-27Announcement

ARPA-H invests in new Alzheimer’s projects to accelerate early detection and treatment | ARPA-H · arpa-h.gov · 2026-10-22 · 2 outletsOfficial

Exeter’s NIHR Policy Research Unit in dementia granted £2 million extension - DevonAir Radio · devonairradio.com · 2026-10-19News

£80m challenge for faster, better dementia diagnosis launched – UKRI · ukri.org · 2026-10-02 · 2 outletsAnnouncement

Risk factors & prevention · 5

Feasibility of an 8-week lifestyle intervention combining exercise, diet, cognitive training, and social engagement in individuals with mild cognitive impairment: a pilot randomized controlled trial - Neuroscience · ibroneuroscience.org · 2026-10-31Research

Dementia prevention — ten modifiable factors · generalpractice.ai · 2026-10-27News

Can We Prevent Cognitive Decline in Aging? Multi-Domain ... · geripal.org · 2026-10-15News

Exercise-based interventions for cognitive frailty in older adults: a systematic review and network meta-analysis | BMC Geriatrics | Springer Nature Link · link.springer.com · 2026-10-14Research

Dementia risk factors may affect women and men differently - Parsemus Foundation · parsemus.org · 2026-10-08News

Dementia care research · 5

Feasibility of a multidimensional interdisciplinary rehabilitation program for people with dementia and their informal primary caregivers – a randomized pilot trial with a caregiver focus | BMC Geriatrics | Springer Nature Link · link.springer.com · 2026-10-21Research

Preliminary findings on the effects of a group-based digital gaming intervention on individuals with early to moderate dementia: a pre- and post-intervention study | BMC Geriatrics | Springer Nature Link · link.springer.com · 2026-10-21Research

UCSF Dementia Clinical Trials for 2026 — San Francisco Bay Area · clinicaltrials.ucsf.edu · 2026-10-14News

Virtual reality for cognitive and neuropsychiatric outcomes in mild cognitive impairment and dementia: a network meta-analysis | npj Digital Medicine · nature.com · 2026-10-06Research

Frontiers | Comparative efficacy of non-pharmacological interventions for amnestic mild cognitive impairment: a network meta-analysis · frontiersin.org · 2026-10-02Research

54 more scanned and set aside

Garvan Institute maps immune gene variants that shape vulner… · dongascience.com · 2026-10-31News

Clinical Trials · healthtree.org · 2026-10-31News

Neurodegeneration - Recent articles and discoveries · link.springer.com · 2026-10-31Research

OncLive - Clinical Oncology News, Cancer Expert Insights · onclive.com · 2026-10-30News

Dementia and Neurodegenerative Diseases · frontiersin.org · 2026-10-30Research

A proof-of-concept test can spot bladder cancer in urine · sciencenews.org · 2026-10-30News

LITMUS Studies Benchmark Non-Invasive MASLD, MASH Tests and … · clpmag.com · 2026-10-30News

Newsdetail – · unimedizin-mainz.de · 2026-10-30News

Reducing Your Dementia Risk · alzca.org · 2026-10-29News

Alliance News · allianceforclinicaltrialsinoncology.org · 2026-10-29News

How to Prevent Dementia: What the Research Shows in 2026 · doctor2me.com · 2026-10-28News

ESMO26: US and FDA movements to improve oncology trials a po… · clinicaltrialsarena.com · 2026-10-28News

Genetic variants that alter gene regulation in specific cell… · nature.com · 2026-10-28News

Alzheimer's and Dementia Hospice Criteria For Healthcare Pro… · wesleylife.org · 2026-10-28News

Genetic Differences Impact Immune Cells to Affect Disease Ri… · insideprecisionmedicine.com · 2026-10-28News

Study Details | NCT07842146 | | ClinicalTrials.gov · clinicaltrials.gov · 2026-10-28Official

Multi-Omics Tools May Improve Diagnosis, Predict Course of P… · rarediseaseadvisor.com · 2026-10-27News

Hospice Criteria for Dementia and Alzheimer's: FAST 7 · betahospice.com · 2026-10-27News

Frontiers in Dementia · frontiersin.org · 2026-10-26Research

Living With a Cognitive Disorder: Sleep, Food & Routines · acibademinternational.com · 2026-10-26News

Dementia · who.int · 2026-10-26Official

There’s a Blood Test for Alzheimer’s · thekey.com · 2026-10-22News

HHS Strategic Response: Alzheimer's Disease · hhs.gov · 2026-10-21Low signal

Choosing and Applying Diagnostic Aids for Cognitive Impairme… · edhub.ama-assn.org · 2026-10-20News

Neuroscience and Neurodegenerative Disease · departments.med.upenn.edu · 2026-10-20News

Thyroid Eye Disease (TED) Clinical Studies | Graves' Disease… · tedcommunity.org · 2026-10-19News

News · worldwide.com · 2026-10-19News

Alzheimer disease · radiopaedia.org · 2026-10-18News

Effectiveness of Non-Pharmacological Interventions in Addres… · sciencedirect.com · 2026-10-16Research

I’m a neurologist. Here’s how to protect your aging brain. |… · psychiatry.ucsf.edu · 2026-10-15Announcement

Improving Cancer Detection: Rethinking Biomarker Measurement… · clpmag.com · 2026-10-15News

Clinical Research News · scopesummit.com · 2026-10-15News

Dementia Drugs Market Size & Forecast 2036 · factmr.com · 2026-10-15Low signal

The impact of biomarkers on the pre-diagnosis and treatment … · sciencedirect.com · 2026-10-14Research

Can Exercise Help Protect Memory and Reduce Alzheimer's ... · mind.uci.edu · 2026-10-13News

Fluid Biomarkers in Alzheimer's Disease and Diagnosis - Neur… · neurotorium.org · 2026-10-13News

What to know about getting tested for Alzheimer’s and other … · healthnationmedia.com · 2026-10-12News

FDA Reviews Evenamide Safety After Four Deaths in Trials · precedenceresearch.com · 2026-10-12Low signal

The use of real‐world data in health services research for ... · alz-journals.onlinelibrary.wiley.com · 2026-10-11Research

Alzheimer's Disease Myths: Aging, Genes And The Evidence · acibademinternational.com · 2026-10-10News

Anti-amyloid antibodies against Alzheimer's disease · pubmed.ncbi.nlm.nih.gov · 2026-10-09Research

Dementia Care: Where Are We Going? The Role of Continuity of… · heraldopenaccess.us · 2026-10-08News

NYU Engineers and Surgeons Funded to Build a Genetic Test Fa… · engineering.nyu.edu · 2026-10-07Announcement

Is Alzheimer's Disease Genetic? Family History and Risk · pantheonclinical.com · 2026-10-07News

How Zorevunersen Works: The Mechanism of Action | NeurologyL… · neurologylive.com · 2026-10-07News

Prevention | UsAgainstAlzheimer's · usagainstalzheimers.org · 2026-10-07News

Population-Scale Proteomics Study Identifies New Genetic-Pro… · labmedica.com · 2026-10-06News

Surprising Ways to Lower Dementia Risk · aultman.org · 2026-10-05News

Frontiers | Ethical challenges in the clinical translation o… · frontiersin.org · 2026-10-05Research

Alzheimer's Blood Test (p-tau217): Who Should Get It and Wha… · mitohealth.com · 2026-10-05News

Genetics Research Funding for Alzheimer's in Maryland · maryland.thegrantportal.com · 2026-10-05News

Tips for Protecting Memory as You Age - Miami Jewish Health · miamijewishhealth.org · 2026-10-05News

Four people with ADAMTS6 variants point to a new connective … · genome.news · 2026-10-03News

Healthy Brain Ageing in Older Adults: An Umbrella Review of … · rsisinternational.org · 2026-10-02News

Tell Iris what to cover more, less, or differently. It shapes your next briefing.

This briefing was generated by Iris Briefings.

Iris uses artificial intelligence to synthesise recent developments in your field. It can make mistakes, so please verify anything critical against the linked primary sources before acting on it. Thank you for supporting Iris.